With over 173,000 studies on PubMed, it's one of the most researched molecules for health and longevity
Growing evidence from observational studies indicates that treatment of obesity with bariatric surgery improves cardiovascular outcomes, but these findings have not been confirmed in randomized trials, largely because of randomization challenges with bariatric surgery
Retatrutide's glucagon activity adds a direct effect on lipid metabolism that may be particularly relevant for people with high triglycerides or fatty liver
Achieve consistent absorption profiles that match published kinetic data

STEP 1 (N = 1,961 adults with obesity, no diabetes): Semaglutide 2.4 mg weekly vs placebo 68-week treatment duration Mean weight loss: 14.9% of baseline body weight (semaglutide) vs 2.4% (placebo) 86% of semaglutide patients lost at least 5% of body weight 69% lost at least 10% 50% lost at least 15% Published in New England Journal of Medicine, 2021 (Wilding et al.) STEP 2 (N = 1,210 adults with obesity and type 2 diabetes): Semaglutide 2.4 mg vs 1 mg vs placebo 68-week duration Mean weight loss: 9.6% (2.4 mg dose) vs 7.0% (1 mg dose) vs 3.4% (placebo) Diabetes patients lose less weight than non-diabetic patients on the same dose, likely due to baseline insulin resistance Published in Lancet, 2021 (Davies et al.) STEP 3 (N = 611, semaglutide plus intensive behavioral therapy): Mean weight loss: 16.0% at 68 weeks Adding structured diet and exercise counseling improved outcomes by approximately 1% absolute weight loss vs medication alone STEP 4 (withdrawal study, N = 803): Patients who achieved weight loss on semaglutide were randomized to continue semaglutide vs switch to placebo Patients who continued semaglutide lost an additional 7.9% of body weight over 48 weeks Patients switched to placebo regained 6.9% of body weight This demonstrates that semaglutide requires ongoing treatment

Lancet 6736(25):22572268